168 related articles for article (PubMed ID: 36051475)
1. Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma.
Fan X; Niu X; Wu Z; Yao L; Chen S; Wan W; Huang B; Qi RQ; Zhang T
Biomed Res Int; 2022; 2022():3168503. PubMed ID: 36051475
[TBL] [Abstract][Full Text] [Related]
2. Aberrant p16, p53 and Ki-67 immunohistochemistry staining patterns can distinguish solitary keratoacanthoma from cutaneous squamous cell carcinoma.
Carr RA; Mesiano D; Heffron C; Radonic T; Wiggins J; Tso S; Agrawal R; Cheung E; Slater DN; Nichols L; Craig P
Pathology; 2023 Oct; 55(6):772-784. PubMed ID: 37573161
[TBL] [Abstract][Full Text] [Related]
3. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Gambichler T; Gnielka M; Rüddel I; Stockfleth E; Stücker M; Schmitz L
Cancer Immunol Immunother; 2017 Sep; 66(9):1199-1204. PubMed ID: 28501937
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing Keratoacanthoma from Well-Differentiated Cutaneous Squamous Cell Carcinoma Using Single-Cell Spatial Pathology.
Veenstra J; Ozog D; Loveless I; Adrianto I; Dimitrion P; Subedi K; Friedman BJ; Zhou L; Mi QS
J Invest Dermatol; 2023 Dec; 143(12):2397-2407.e8. PubMed ID: 37419445
[TBL] [Abstract][Full Text] [Related]
5. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma.
Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
Br J Dermatol; 2001 Oct; 145(4):582-9. PubMed ID: 11703284
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen distribution in keratoacanthoma and squamous cell carcinoma.
Phillips P; Helm KF
J Cutan Pathol; 1993 Oct; 20(5):424-8. PubMed ID: 7507945
[TBL] [Abstract][Full Text] [Related]
7. Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant.
Sánchez Yus E; Simón P; Requena L; Ambrojo P; de Eusebio E
Am J Dermatopathol; 2000 Aug; 22(4):305-10. PubMed ID: 10949454
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
9. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors.
Cain CT; Niemann TH; Argenyi ZB
Am J Dermatopathol; 1995 Aug; 17(4):324-31. PubMed ID: 8600793
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
Biesterfeld S; Josef J
Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
[TBL] [Abstract][Full Text] [Related]
11. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
[TBL] [Abstract][Full Text] [Related]
12. A clinical and biological review of keratoacanthoma.
Tisack A; Fotouhi A; Fidai C; Friedman BJ; Ozog D; Veenstra J
Br J Dermatol; 2021 Sep; 185(3):487-498. PubMed ID: 33864244
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin.
Krunic AL; Garrod DR; Madani S; Buchanan MD; Clark RE
Br J Cancer; 1998 Apr; 77(8):1275-9. PubMed ID: 9579833
[TBL] [Abstract][Full Text] [Related]
14. Debulking followed by intralesional 5-fluorouracil for the treatment of cutaneous squamous cell carcinoma and keratoacanthoma: A retrospective analysis.
Hamad J; Jolly PS
Dermatol Ther; 2021 Nov; 34(6):e15139. PubMed ID: 34549487
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma.
Leblebici C; Pasaoglu E; Kelten C; Darakci S; Dursun N
Oncol Lett; 2017 Apr; 13(4):2539-2548. PubMed ID: 28454431
[TBL] [Abstract][Full Text] [Related]
16. Plasmacytoid dendritic cells in keratoacanthoma and squamous cell carcinoma: A blinded study of CD123 as a diagnostic marker.
Fraga GR; Chow P
J Cutan Pathol; 2020 Jan; 47(1):17-21. PubMed ID: 31449667
[TBL] [Abstract][Full Text] [Related]
17. EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study.
Jacobs MS; Persons DL; Fraga GR
J Cutan Pathol; 2013 May; 40(5):447-54. PubMed ID: 23521519
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
Vasiljević N; Andersson K; Bjelkenkrantz K; Kjellström C; Månsson H; Nilsson E; Landberg G; Dillner J; Forslund O
Int J Cancer; 2009 May; 124(10):2361-6. PubMed ID: 19165861
[TBL] [Abstract][Full Text] [Related]
19. Low detection rate of human papillomavirus in patients with cutaneous squamous cell carcinoma and keratoacanthoma.
Baek YS; Kim YC; Kim KE; Jeon J; Kim A; Song HJ; Kim C
Eur J Dermatol; 2022 Sep; 32(5):577-583. PubMed ID: 36468731
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma.
Scola N; Segert HM; Stücker M; Altmeyer P; Gambichler T; Kreuter A
Clin Exp Dermatol; 2014 Mar; 39(2):216-8. PubMed ID: 24524559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
